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Abstract: Introduction: The scope of pharmacy practice has evolved over the last few decades
to focus on the optimization of medication therapy. Despite this positive impact, the lack of
reimbursement remains a significant barrier to the implementation of innovative pharmacist
practice models. Summary: We describe the successful development, implementation and
outcomes of three types of pharmacist collaborative care models: (1) a pharmacist with physician
oversight, (2) pharmacist–interprofessional teams and (3) physician–pharmacist teams. The outcome
measurement of these pharmacist care models varied from the design phase to patient volume
measurement and to comprehensive quality dashboards. All of these practice models have been
successfully funded by affiliated health systems or grants. Conclusions: The expansion of pharmacist
services delivered by clinical faculty has several benefits to affiliated health systems: (1) significant
improvements in patient care quality, (2) access to experts in specialty areas, and (3) the dissemination
of outcomes with national and international recognition, increasing the visibility of the health system.
Keywords: collaborative practice; clinical pharmacy; advanced practice pharmacist provider
1. Introduction
Collaborative care between pharmacists and physicians has been recognized to improve
pharmacotherapeutic outcomes and provide increased value and efficiency to the health care system [1].
Models for collaborative drug therapy management have been designed with a focus on the most
studied chronic diseases including hypertension (HTN) and type 2 diabetes (T2D). Numerous studies
have demonstrated the positive impact that physician–pharmacist collaborative management can
have on blood pressure and glycosylated hemoglobin (A1C) among patients with HTN and DM [2–4].
Additionally, this positive impact has been demonstrated for other chronic diseases [5,6]. More recently,
Matzke and colleagues demonstrated that pharmacists integrated in a patient-centered medical
home reduce hospitalizations by 23.4%, resulting in estimated cost savings of $2619 per patient [7].
Despite the overwhelmingly positive impact of pharmacist services on patient outcomes, the integration
Pharmacy 2019, 7, 142; doi:10.3390/pharmacy7040142 www.mdpi.com/journal/pharmacy
Pharmacy 2019, 7, 142 2 of 14
of pharmacists in ambulatory care programs is not widespread. A survey conducted by Hattingh and
colleagues identified three major themes as factors that impacted the provision of pharmacist services:
(1) pharmacist characteristics, (2) local needs, structures and support, and (3) an enabling practice
framework [8,9]. In this paper, we describe the program development, successful implementation and
outcomes of pharmacist collaborative care models provided by the University of California, San Diego
Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) faculty in two affiliated academic
health systems.
Setting
For decades, the scope of pharmacy practice in the United States (US) has expanded to optimize
medication use to achieve patient health-related goals. More recently, the passage of California
Senate Bill 493 allows all pharmacists to administer drugs and biologics when ordered by a prescriber,
furnish oral contraceptives, travel medications and nicotine replacement products for smoking
cessation, as well as administer vaccinations. This bill established an Advanced Practice Pharmacist
(APP) recognition and authorizes APPs to perform patient assessments, order and interpret drug
therapy–related tests, refer patients to other health care providers, initiate, adjust, and discontinue
drug therapy upon referral from a patient’s treating prescriber and in accordance with established
protocols, and participate in the evaluation and management of diseases and health conditions in
collaboration with other health care providers. The APP recognition requires a separate APh licensure
application, review and approval from the California Board of Pharmacy.
At UC San Diego Health (UCSDH) and the Veteran’s Affairs San Diego Healthcare System
(VASDHS), comprehensive collaborations were developed in which pharmacists provide patient
care under collaborative practice agreements (CPA) in the inpatient and ambulatory care settings.
The positive impact of pharmacist services has been established using various models of care for
chronic disease management [10–12]. However, recognition of pharmacists as providers has been
challenged, and reimbursement for services has been limited. The lack of reimbursement for services
creates a barrier to the implementation of new pharmacist care models in health systems [13].
2. Health System Overview
UCSDH is a comprehensive health system with an average daily census of approximately
600 patients and over 580,000 ambulatory care visits per year. Approximately 12 faculty from
SSPPS provide collaborative care within the health system. Since 2010, the UCSDH pharmacy
department developed a program expanding the role of the pharmacist in inpatient and ambulatory
care and affiliated clinic settings. VASDHS provides care to more than 249,594 Veterans in the San
Diego and Imperial Valley counties. In addition to the main facility in San Diego, VASDHS has six
community-based outpatient clinics. Two faculty from SSPPS provide patient care within VASDHS.
Faculty partner with staff pharmacists within each affiliated health system to develop new services.
CPAs were developed and implemented for practice areas including chronic kidney disease (CKD),
diabetes, family medicine, heart failure (HF), oncology, pain and palliative care, psychiatry, solid organ
transplantation (SOT), and transitions of care (TOC). Collaborative care is delivered using three main
care models: (1) pharmacists with physician oversight, (2) pharmacist–interprofessional teams, and (3)
physician–pharmacist teams.
2.1. Needs Assessment and Proposal Development
Each program arose from a clinical need identified by the health system or through a needs
assessment conducted by individual faculty with subspecialty expertise. Some needs were based
on regulatory requirements (e.g., solid organ transplant), gaps identified by a physician champion,
or grant funding available for novel clinical services. Initial steps include proposal development,
identified gaps in care, proposed outcome measures, and a business case for return on investment.
All pharmacist practices were successfully funded by affiliated health systems or grants.
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2.2. Implementation
A multi-professional, collaborative approach involving pharmacists, physicians, nurses and
administration personnel was required to establish and streamline the patient care process for the target
population. Clinical program development included creating a scope of practice and credentialing,
clinical guidelines or protocols, clinic schedules and space, referral criteria and documentation templates
in the electronic health record (EHR). In each affiliated practice setting, the pharmacist–physician team
determined the pharmacist scope of practice. Within the scope of practice, prescribing authorities were
defined for specific diseases or conditions. These authorities include the initiation, adjustment and
discontinuation of medications according to program-specific clinical guidelines or health system
policies, where appropriate. Pharmacists have the authority to order medication-related tests
(i.e., laboratory, pharmacogenomic and radiographic tests) to monitor therapy outcomes and make
referrals to other providers. The CPA is not limited to specific medications (with the exception of
controlled substances, where this is required by the Drug Enforcement Agency), providing prescribing
flexibility. All pharmacists who wished to establish a CPA with a physician must have been licensed
in California and demonstrate experience and competence treating patients within their specialty in
order to be credentialed through their respective health system.
2.3. Outcome Measurement
EHRs enable the measurement of patient care clinical and process outcomes. Each program is
responsible for defining, measuring and reporting care outcomes. Collaborative practice outcome
measurements are in different phases, with some at the design phase and others using comprehensive
dashboards. Dashboards are useful tools for tracking outcome measures and identifying areas for
performance improvement. However, this approach is largely retrospective and dependent on the
frequency of outcome trending. EHR disease registries are used to capture, manage and provide
access to condition-specific information for a specified group of patients to support organized clinical
care [14,15]. Registries enable point of care integration with clinical practice guidelines, outreach to
patients between visits to address care gaps and periodic evaluation of aggregate data and performance
to manage a population [16]. Several registries have been developed at UCSDH and VASDHS for
patients with conditions such as CKD, T2D and thrombotic disorders.
3. Collaborative Care Models
3.1. Pharmacist with Physician Oversight Care Model
3.1.1. VASDHS Diabetes Intense Medical Management “Tune Up” Clinic
In 2009, a needs assessment identified over 9600 Veteran patients had a diabetes diagnosis and
A1C values > 9% (per internal VASDHS VISN 22 Registry Data). In May 2009, the Diabetes Intense Medical
Management (DIMM) “Tune Up” Clinic was created as a collaborative pharmacist–endocrinologist
clinic to manage complex T2D patients and help them achieve clinical goals (e.g., A1C, blood pressure,
lipid, weight goals) within 6 months. The clinical pharmacist specialist employs a short-term model
that couples personalized clinical care with patient-specific diabetes education during an average of
three 60 min visits over 6 months. After achieving goals, patients are referred back to their primary care
provider (PCP). This allows a collaborative effort between the PCP and the pharmacist, frees up time
during PCP visits to address other patient disorders, and provides patients with lifelong skills to manage
their T2D and related metabolic disorders. The intended outcomes were to help PCPs and the medical
center to achieve performance measures, avoid health system costs to treat diabetes complications,
and prevent or delay patients from experiencing costly long-term complications of diabetes. Prior to
implementation, the DIMM “Tune Up” clinic was reviewed, approved, and supported by key decision
makers at the medical center: the Chief of Pharmacy, the Chief of Endocrinology, and the Chief of Internal
Medicine, representing the PCPs.
Pharmacy 2019, 7, 142 4 of 14
Clinical issues, comorbidities, complications, socioeconomic and behavioral issues are integrated
and assessed using the MTM Spider Web©, a visual tool developed for systematically creating a
patient-centered clinical care plan [17]. The comprehensive nature of the tool helps ensure completeness
and accuracy, as well as aiding patients to participate in shared decision-making while improving
awareness and knowledge to assist in self-advocacy in their care. Strong emphasis is placed on
adherence and educating and empowering patients to take control of their own diabetes without
hypoglycemic events. Patients receive an individualized action plan and a personal medication record
at each visit.
DIMM clinic outcomes demonstrate a 2.4% reduction in A1C compared to 0.8% in a PCP control
group within 6 months, and glycemic control was achieved without significantly impacting medication
regimen complexity [18,19]. A pharmacoeconomic analysis demonstrated that DIMM Clinic care
resulted in $5287 savings per patient compared to usual PCP care, translating to a $9 to $1 return on
investment [20]. Cost savings to the institution and reimbursement from insurance, as well as the
strong metabolic outcomes, have justified continued clinic funding.
3.1.2. UCSDH Diabetes Self-Management
The Diabetes Self-Management Program is an ambulatory care clinic providing diabetes
self-management education for up to 350 patients annually with pre-diabetes or T2D. This program
was developed, implemented and led by two pharmacists and a physician champion. Subsequently,
it was accredited by the Diabetes Education Accreditation Program enabling insurance billing.
The pharmacists are funded by the medical group and provide care following a CPA. Patients are
referred by their UCSDH provider for group classes or individual visits at four different UCSDH
outpatient clinics. The group education classes consist of two core, two-hour classes, each 1–2
weeks apart, covering seven diabetes self-management topics. For patients with cognitive deficits,
hearing or visual impairment, a language barrier, or those requiring insulin initiation, individual
60 min visits are preferred. Services provided include medication reconciliation and the assessment of
adherence, nutrition habits, and glucose meter results, with education tailored to patient’s specific
needs. All patients set specific behavioral goals for themselves. Pharmacist recommendations are
electronically sent to the referring provider after the visit. Telephone follow-up occurs 1–2 weeks
following the classes or visits.
Annually, the program has over 500 office visits and 300 telephone follow ups. For group
education, 45.8% patients attended one or two group meetings, and 13.2% attended three or four
group meetings; the remaining patients were seen individually [21]. The mean decrease in A1C at
6 months was −0.6% compared to usual care −0.2%, p < 0.001, with no significant change in body mass
index [21]. The program has also demonstrated a reduction in the number of patients with A1C > 8%,
resulting in 55% achieving A1C <8% after 3 months and improved screening for A1C, with 57% of
patients receiving two or more screenings per year. The outcomes have enabled continued funding of
the program and the addition of a dietician (0.1 FTE) and scheduler (0.2 FTE).
3.1.3. VASDHS Heart Failure Medication Management Clinic
Established in 2012, the HF medication management clinic objective was to reduce HF readmissions
and improve outcomes in collaboration with the VA Advanced HF Team comprising cardiologists,
nurse practitioners and nurses. The pharmacists’ scope of practice includes prescribing HF-related
medications and ordering relevant laboratory and diagnostic studies. The advanced HF team establishes
a diagnosis and initiates treatment, then referring patients for 30 to 60 min visits focused on medication
management and follow-up. The pharmacist evaluates volume overload and worsening signs of
congestion, titrates neurohormonal blockade to target doses, adjusts diuretics, assesses medication
adherence and adverse effects. Typical medication titration visits can occur every 2–4 weeks,
whereas patients requiring frequent diuretic adjustment may be seen weekly. The pharmacist works
with the VASDHS quality improvement team to improve HF care and reduce hospital readmissions.
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3.1.4. SSPPS Partners in Medication Therapy (PMT)
PMT was established to provide medication therapy management services to self-insured
employers, medical groups, and health plans. Services include optimizing medications and patient
education on medication therapy for chronic diseases such as T2D, asthma, and cardiovascular disease.
Partnerships with large third-party health plans generated opportunities for SSPPS APPs to work
with different PCPs in Independent Practice Associations to provide telehealth visits. Patients were
identified and referred to the APP based on gaps in therapy, adherence problems, or lack of treatment
goal attainment detected by the health plan pharmacy claims data or the EHR. Clinical protocols
were developed for chronic conditions such as HTN and T2D as well as therapeutic interchange to
reduce drug costs. Under a CPA, APPs were authorized to initiate, modify, substitute, or discontinue
agreed-upon medications according to the protocol and to authorize refills.
Using individual medical group EHR remote access, four APPs performed one-hour phone
sessions to provide comprehensive medication management, order labs, document recommendations
and communicate with PCP as needed. Each patient received an updated medication list and action
plan. Follow up frequency was determined by patient-specific needs. Patients were discharged after
goal attainment or failure to have detectable improvement after 6 to 12 months. In an initial four-month
pilot program with St. Joseph Heritage Healthcare (Orange County, CA, USA), 756 patients were
referred and screened with 61 resulting appointments.
3.2. Interprofessional (IP) Care Model
3.2.1. UCSDH Chronic Kidney Disease (CKD)
In 2007, the CKD program was developed as an ambulatory clinic providing evidence-based IP
care to delay CKD progression for approximately 400 patients with CKD Stages 2–5. UCSDHS funded
the program as a separate cost center allowing financial outcomes including office visit volumes,
medication revenue and expenses to be measured. The team consists of a nephrologist, pharmacist,
nurse, dietitian and social worker. Patients see all team members at each visit, with new visits lasting
approximately 90 min and return visits 60 min.
Under a CPA, the pharmacist conducts medication reconciliation, adherence assessment,
and comprehensive medication management, facilitates access to medications, and provides patient
education on changes to the medication therapy plan as well as the patient’s progress towards their
health-related outcomes. The pharmacist optimizes medication therapy for hypertension, diabetes,
proteinuria, hyperlipidemia, anemia, bone disease, hyperkalemia, metabolic acidosis and vaccinations.
The pharmacist estimates kidney function and adjusts the doses of medications. The pharmacist orders
prescriptions to the community pharmacy, medications to be administered in clinic, vaccinations and
medications to be administered in the infusion centers. Patients receive one-on-one education during
their clinic visit, are provided links to online education videos (developed by the CKD Program),
and can attend a group class on dialysis modalities and kidney transplantation.
Implementation barriers included the expense of an IP team and low insurance reimbursement
rates. Additionally, the pharmacist, social worker, and dietitian could not bill the insurers for their
individual services, and the physician could not bill more complex office visits for services provided
by the team. To minimize facility overhead expenses, the CKD program operates clinics in the same
physical space as general nephrology clinics. Clinic volumes are at capacity, and the expansion of
the program has been limited due to cost and available space. Despite challenges with expansion,
this program has been sustained with a steady stream of new referrals.
This program was the first in the US to receive disease-specific certification in CKD from the Joint
Commission, demonstrating high-quality care to patients [22]. Clinical and process outcomes routinely
measured include but are not limited to blood pressure control, non-steroidal anti-inflammatory drug
(NSAID) usage and counseling on avoidance, sick day management with angiotensin converting
enzyme inhibitors or angiotensin receptor blockers, and referral for vascular access and transplantation
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as well as vaccination rates. With over 1000 office visits per year, the team achieved systolic blood
pressure control in 58% of patients, with 0% of patients prescribed NSAIDs, 98% counselled to avoid
NSAID products, and 64% viewing online CKD educational videos [23].
3.2.2. UCSDH Oncology
Moores Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer
Center in San Diego, provides over 56,000 cancer patient visits annually including approximately
200 autologous and allogeneic hematopoietic stem cell transplants.
In 2014, the clinical pharmacy program was developed and implemented by a pharmacist in
collaboration with a physician champion. Funding was provided by the cancer center for clinical
services for two full days per week. The pharmacist initially developed a clinical practice in the
thoracic medical oncology and the blood and marrow transplant departments. After one year of
practicing, the pharmacist collaborated with leadership to expand the clinical pharmacy program by
one full-time equivalent clinical pharmacy specialist in the head and neck/thoracic medical oncology
ambulatory clinics.
The IP teams consist of oncologists, pharmacists, nurse case managers, mid-level providers
(nurse practitioners and physician assistants), and medical assistants with the support of a social
worker and a nutritionist on an as-needed basis. Clinical services provided by the pharmacist include
medication management under a CPA, conducting medication reconciliation, oral chemotherapy
adherence assessment, symptom management, immunization screening and ordering, therapeutic
drug monitoring, oncology stewardship, and chemotherapy order preparation. The pharmacist
provides literature support for the off-label utilization of cancer treatments. In addition, patients
receive one-on-one education with the pharmacist or attend a group class focused on Chemotherapy
and Immunotherapy Treatment that was developed and implemented by the pharmacist.
3.2.3. UCSDH Pain and Palliative Care
The ambulatory and inpatient palliative care IP consult team is comprised of physicians,
pharmacists, social workers, nurse practitioners and a chaplain. A description of the CPA development
has been previously published [24]. In accordance with California code 4052, UCSDH palliative care
pharmacists have independent prescriptive authority, with Drug Enforcement Agency (DEA) licensure
and National Provider Index (NPI) status. Reasons for pharmacist consultation included physical
symptom management, including but not limited to cancer-related pain, constipation, nausea and
vomiting, fatigue, and insomnia.
Initial studies evaluating palliative care pharmacist contributions in the ambulatory care and
inpatient settings have been positive [25–27]. Patients seen in clinic by a palliative care pharmacist
versus patients who received standard of care showed trends for better pain control and health-related
quality of life and function [26]. Medication prescribing changes by palliative care pharmacists
commonly include a change in dose and/or the initiation of a new medication [27]. Positive trends were
observed in pain control for patients with cancer over subsequent clinic visits [27]. Analgesic efficacy
was improved by 17% and non-adherence was reduced by 13% [27].
Additionally, in the inpatient setting, the palliative care pharmacist provides opioid stewardship
and guideline development for safe and effective analgesia. Prescribing trends are evaluated for
safety and efficacy. Areas of focus include but are not limited to the prescription of fentanyl
patches, patient-controlled analgesia, gabapentinoids, ketamine oral and intravenous infusion,
lidocaine intravenous infusion, mexiletine, methadone, and naloxone [23,28–36]. Guidelines for
the appropriate use of end-of-life opioids were developed [37]. Early access to the inpatient palliative
care pharmacist resulted in a shortened length of stay, shortened length from admission to palliative
care consult, and a positive impact on time from consult to discharge or death [25].
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3.2.4. UCSDH Solid Organ Transplantation
The Solid Organ Transplant program is a comprehensive IP center that provides evidenced-based,
full-spectrum care from pre-transplant evaluation to post-transplant management for patients needing
a kidney, pancreas, liver, lung, or heart transplant. The teams consist of transplant physician
specialists (i.e., nephrologist, hepatologist, cardiologist, etc.), transplant surgeons, pharmacists, nurses,
dietitians, and social workers. In 2004, the bylaws of the United Network for Organ Sharing were
amended to include pharmacists as necessary providers on the transplant team [38]. There are eight
dedicated transplant pharmacists, including two faculty pharmacists who each devote 15% effort to
ambulatory patient care and receive salary support from the UCSDHS Center for Transplantation.
Revenue generated by improving patient utilization of discharge and ambulatory UCSDH pharmacies
has led to expansion and continued salary support for transplant pharmacists.
Similar to other services in the health system, transplant pharmacists initiate, discontinue,
change, and monitor drug therapy under a CPA. Working closely with transplant physicians and
surgeons, pharmacists manage a patient’s immunosuppressive therapies, as well as treatments for
complications of immunosuppression, other associated medical conditions, and preventative therapies.
The pharmacists conduct medication reconciliation, adherence assessment, a focused assessment
of immunosuppression, MTM for various complications of transplantation, order laboratory tests,
immunizations, facilitate access to medications and provide comprehensive patient education. In 2018,
approximately 95 kidney, 41 liver, 56 heart, and 23 lung transplants were performed, and long-term
follow-up was provided.
3.2.5. UCSDH Transitions of Care (TOC)
The TOC program aims to optimize care and reduce hospital readmissions by providing hospital
and ambulatory care continuity services for approximately 7800 high-risk patients within UCSDH.
Funding support for the TOC program was initially driven by Medicare incentive programs such
as Delivery System Reform Incentive Payment (DSRIP) and the Community-Based Care Transitions
Program (CCTP) to improve care transitions for high-risk patients. The TOC pilot program was
implemented by a pharmacist to target patients with advanced stages of HF. Following the conclusion
of the DSRIP and CCTP projects, funding from UCSDH was justified with documented interventions
from the pilot programs. The TOC pharmacist service has since expanded to include other populations
(e.g., HIV) and select groups of managed care patients. An SSPPS faculty member joined the TOC
program with UCSDH funding support of 40% in an effort to assist with the increased breadth of
patient services.
TOC pharmacists work under a CPA with prescribing authority to initiate, adjust, monitor,
or discontinue medication therapy for HF and related conditions in hospital and ambulatory
clinics. Inpatient TOC pharmacists make rounds daily with an IP team, conduct admission and
discharge medication reconciliation, assess adherence, collaborate with the medical team on medication
therapy, facilitate access to medications, and provide comprehensive patient education. Ambulatory
TOC pharmacists perform phone-call follow-up and focus on post-discharge patients in-clinic to
conduct medication reconciliation, assess adherence, perform MTM for HF and related conditions,
facilitate medication access, and provide patient education.
Given the expense of pharmacist salaries and the inability to bill insurers for pharmacist services,
funding remains the primary barrier to expanding the TOC program. Funding for pharmacy technicians
and longitudinal TOC introductory pharmacy practice experiences for pharmacy students have been
implemented to maximize budget resources. Approximately 70% of patients require a pharmacist
intervention, with an average of two interventions per patient.
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3.3. Pharmacist-Physician Team Care Model
3.3.1. UCSDH Family Medicine Clinics
The UCSDH Family Medicine Clinics provide services at three locations throughout San Diego
County to patients from pre-conception to end-of-life care. Since 2010, two clinical pharmacists
have provided chronic disease management under a CPA. Patients are identified by the PCP and
are referred for a “shared” collaborative visit with a pharmacist and a family medicine physician.
During each visit, the pharmacist conducts medication reconciliation and reviews the patient’s past
medical history, relevant family and social histories, risk factors, allergies, medications, and lab
results. Pharmacists manage anticoagulation, diabetes, HTN, hyperlipidemia, tobacco cessation,
and immunizations. A care plan is developed with the patient that includes treatment goals and
education. The plan is communicated with the physician, who also meets with the patient to address
any further questions or health problems. Based on the complexity of the visit, insurance is billed with
the physician signing off on the care plan. The PCP is also notified of the care plan. Patients are seen in
30 min appointments with regular follow-up, accounting for over 1000 annual office visits.
Ongoing and regular physician referrals remain a challenge. Patients may also be identified
through EHR registries or dashboards and then scheduled for a pharmacist visit, although patients
are more likely to attend visits when suggested by their PCP. Additionally, since the physician paired
with each pharmacist is different at each session, it is not always guaranteed that a patients’ own
PCP will be the physician during their shared visit. The physician sees his/her own limited set of
patients for the session, and so challenges arise with respect to timing and visit duration, impacting the
patient and provider experience. While these types of visits do increase IP collaboration and allow for
more complex visits and reimbursement, there have been discussions about moving toward a more
independent-pharmacist model within the clinics.
Clinical outcome measures being implemented include improved A1C, anticoagulation time in the
therapeutic range, the achievement of goal blood pressure, and the primary and secondary prevention
of coronary artery disease and stroke. This particular program was selected as one of three in 2018 by
the Centers for Disease Control and Prevention for an evaluability assessment site visit as a program
routinely using innovative strategies in hypertension care [39].
3.3.2. Geriatric Community Partnerships
In 2015, UCSDH was awarded a grant from the federal Health Resources Services Administration
Geriatrics Workforce Enhancement Program (GWEP) of the Department of Health and Human Services
to train and research novel approaches to providing older adult care. One particular focus of this
proposal was the incorporation of a clinical pharmacist in a primary care clinic to provide direct-patient
care for underserved populations via a partnership with the Medicare–Medicaid-funded Program
of All-Inclusive Care for the Elderly (PACE) Clinic in San Ysidro, CA, and to train and embed a
pharmacist fellow in the clinic to perform comprehensive medication management under a CPA [40].
The funding also supported a part-time student pharmacist to assist with clinic provider education
on potentially inappropriate medications, polypharmacy, medication regimen complexity, program
development, and participation in required rapid-cycle quality improvement projects [41]. The patient
population was 90% percent Spanish-speaking, with limited health literacy and, as Medicaid qualifiers,
they were low-income patients with an average of 14 medications per patient. The pharmacist conducts
transitions of care medication reconciliation, manages anticoagulant dosing, initiates immunizations,
reduces the use of inappropriate medication and high-cost medications, and provides medication
usage recommendations to center management [42]. The clinic has continued its funding of a full-time
clinical pharmacist.
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3.3.3. UCSDH Psychiatry
UCSDH Outpatient Psychiatry Services include general psychiatry and specialty clinics in mental
health such as college mental health, child and teen psychiatry, addiction treatment, treatment-resistant
depression, women’s reproductive mental health, sexual health, early psychosis, and senior behavioral
health. The clinics employ numerous health professionals to provide a full range of outpatient
psychiatric services, including intakes, individual and group psychotherapy, pharmacotherapy,
and psychoeducation. Established in 2008 [43], the pharmacist clinic has experienced between
approximately 150–300 annual office visits [43]. The patient population varies from county-funded
patients with severe mental illness to public and private funding for mood disorders, anxiety disorders,
PTSD, and ADHD. The Department of Psychiatry provides funding for 10% work for the psychiatric
pharmacist’s clinic time.
During each visit, the psychiatric pharmacist spends approximately 30–45 min providing
psychotropic medication management under a CPA. The pharmacist conducts medication reconciliation,
assesses medication adherence and adverse effects, evaluates medication dosing, assists with refills
and insurance authorizations, and makes referrals to other services. The pharmacist and attending
psychiatrist develop the therapeutic plan and then discuss the plan with the patient. The pharmacist
has a DEA license, which allows the initiation and modification of controlled and non-controlled
medications. Recently, the pharmacist coordinated the initiation of a new, long-acting, injectable
antipsychotic program to improve patient access and continuity of care.
Implementation challenges include funding for the pharmacist’s work, insurance billing,
shared visit scheduling, and regulatory requirements for documentation. Program outcomes include
patient encounter volumes, top patient diagnosis, and pharmacist interventions. Future program
outcomes will include symptom improvement using standard rating scales and required medication
monitoring documentation.
4. Discussion
In this paper, we describe collaborative pharmacist–physician practice models that provide clinical
care to patients with complex disease states. The pharmacists not only focus on the optimization
of care for their respective specialties but also provide comprehensive care for comorbid conditions
and complications. Notably, the pharmacists provide a large scope of services which encompass
medication therapy management, including but not limited to medication reconciliation, initiating and
adjusting medications, the ordering and monitoring of laboratory tests, performing physical
examination, assessing and optimizing adherence, promoting healthy lifestyles, and providing
education. These services were delivered using different care models integrating the pharmacist within
IP teams or partnering with physicians.
The type of practice model chosen was based on the disease state, patient complexity,
needs assessment, strategic goals, and financial viability. We summarized the advantages and
disadvantages for the described care models (Table 1). For example, the DIMM clinic model is a
pharmacist with physician oversight model since evidence-based medication optimization to improve
glycemic control could be most efficiently delivered by the pharmacist provider. However, in psychiatry,
the pharmacist–physician team care model was chosen due to patient complexity and the need for an
individualized approach to management that considers numerous patient factors.
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Table 1. Advantages and disadvantages of different pharmacist care models.
Care Model Advantages Disadvantages
Pharmacist with
physician oversight
Autonomy in clinical decision making.
Efficient model for optimizing medication
management using evidence-based guidelines.
Improves public recognition of advanced
pharmacist provider roles.
Can only be applied to patients with established
diagnosis who mainly require optimization of
medications.
Complex patients requiring additional diagnostic
testing may not be appropriate.
Pharmacist may feel a disconnect from physician
collaborator.
Dependent on referrals from physician
collaborators.
Low reimbursement on visits in the United States.
Interprofessional
Best suited for complex disease states or
patients with numerous comorbidities.
Patient convenience-comprehensive care
delivered in one single office visit.
Greater ability to achieve target clinical
outcomes with multi-prong management (e.g.,
lifestyle modification, medications, social
interventions)
Higher reimbursement since physician
provider bills for visits.
Requires greater coordination of team members
during visits to ensure efficiency.
Less time for each health professional to spend
with patient.
Longer visit duration for patients.
Longer visits may result in lower patient volumes.
Interprofessional team is resource intensive.
Pharmacist-Physician
Team
Can manage established and newly diagnosed
patients who may require additional diagnostic
testing.
Enhances care provided in physician only visits
due to optimization of drug therapy.
Easier to coordinate team members.
Higher reimbursement since physician
provider bills for visits.
Less pharmacist autonomy
Longer visits
Dependent on referrals for patient volume.
Importantly, the majority of these care models have been funded by the affiliated health systems,
and a few are funded by grant mechanisms. This was made possible by creating goals that align with
the health system priority initiatives and recruiting faculty whose expertise could help to achieve these
goals. A business case was developed by reviewing published literature, identifying potential quality
outcomes and direct and indirect financial metrics. Several studies have been published demonstrating
the financial benefit of pharmacist care services in a variety of care environments from community
pharmacy to ambulatory care clinics and to hospital acute care environments. In a study examining the
impact of the community pharmacist-initiated management of uncomplicated urinary tract infections,
pharmacist care was associated with lower costs ($72.47) when compared to family ($141.53) and
emergency ($368.16) physician-initiated care, estimated to result in significant long-term net total
savings of $51 million [44]. Ourth and colleagues conducted a cost-effectiveness study of clinical
pharmacists managing diabetes and found a negative cost per quality of life adjusted years after 3 years,
suggesting that it is cost-effective to incorporate pharmacists into diabetes care teams [45]. Similarly,
studies of transitions of care programs have demonstrated significant cost savings. Ni and colleagues
documented average cost savings of $2139 in the first 180 days after discharge [46].
The practices described in this paper proved to be sustainable with continued funding for
long periods of time despite cessation of grant funding. Moore and colleagues found that after
initially funding pharmacist services through grant mechanisms and demonstrating quality care,
the services could be continued and expanded through funding by accountable care organizations [47].
We demonstrate that clinical faculty can effectively provide comprehensive pharmacist services to
a large breadth of complex patient populations across multiple practice settings in affiliated health
systems. Our programs position pharmacists to obtain APP status in the future given their collaborative
practice meets necessary criteria for APh licensure.
We stated that the outcome measurement of these pharmacist care models varies with some
practices in the design phase and others measuring patient volume to robust clinical and process
outcome dashboards. Successful programs measure meaningful outcomes that demonstrate the
return on investment for the health system. Many of our programs have developed significant
Pharmacy 2019, 7, 142 11 of 14
improvements in clinical and process outcomes. We demonstrated that pharmacist-delivered diabetes
care resulted in A1c reductions of 2.4%, compared to 0.8% for standard of care, with significant cost
savings. The pharmacist within the IP CKD care team focused on reducing the number of patients
prescribed an NSAID to 0% and counseling over 98% patients on NSAID avoidance. In palliative
care, pharmacist interventions resulted in 17% improved medication efficacy and a reduction in
non-adherence by 13%. Transitions of care pharmacists demonstrated a significant reduction in hospital
readmissions with cost savings to the institution. These clinical and process outcomes have been
revised as needed for continuous quality improvement, with the retirement of outcomes at goal and
new outcomes identified. In some instances, new outcomes or strategies were developed for financial
sustainability. These results have been disseminated at national and international IP conferences,
or published in journals with broad readership. This dissemination is critical to allow for these care
models to be easily replicated at other institutions.
The value of pharmacist services we described has received notable recognition from government
agencies, accreditation bodies, and professional societies. From these various models of pharmacist
services, we identified some common facilitators. These included a gap in care that could be met
with pharmacist services, a linkage between clinical and financial outcomes, a physician champion
to support proposals, and the strategic recruitment of faculty with expertise in these growth areas at
affiliated health systems.
Program design and implementation always comes with challenges; space and funding are
well-recognized resource barriers. However, our collective approach has been to share our faculty
experiences and to brainstorm funding mechanisms and develop successful space propositions such as
colocation. The colocation of interprofessional team members in a shared work space and elimination
of private physician work offices has been shown to improve team communication, cohesiveness,
and team primacy [48]. An important facilitator of funding challenges is the joint appointment of the
UCSDH Chief Pharmacy Officer as a clinical faculty member that provides a critical advantage for the
development of new clinical services at UCSDH. Our future directions include the development of new
clinical faculty practice settings in geriatrics and infectious disease within the affiliated health systems.
5. Conclusions
In conclusion, the expansion of pharmacist services delivered by clinical faculty has several
benefits to affiliated health systems: (1) significant improvements in patient care quality, (2) access
to experts in specialty areas, and (3) the dissemination of outcomes and national and international
recognition, increasing the visibility of the health system.
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